NCT01694277View on ClinicalTrials.gov

Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib

PHASE3CompletedINTERVENTIONAL
Enrollment

258

Participants

Timeline

Start Date

April 30, 2012

Primary Completion Date

December 31, 2020

Study Completion Date

December 31, 2020

Conditions
Gastrointestinal Stromal Tumors
Interventions
DRUG

Masitinib

12 mg/kg/day

DRUG

Sunitinib

50 mg/day

Trial Locations (5)

10060

Istituto per la Ricerca e la Cura del Cancro (IRCC), Candiolo

33000

Institut Bergonié, Bordeaux

63110

Washington University School of Medicine, St Louis

06202

Hôpital l'Archet 2- Service de Cancérologie Digestive, Nice

3015 GD

Erasmus University Medical Center, Rotterdam

Sponsors

Lead Sponsor

AB Science
All Listed Sponsors
lead

AB Science

INDUSTRY